Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images
- Conditions
- Nasopharyngeal CarcinomaImage-Guided Biopsy
- Registration Number
- NCT05202626
- Lead Sponsor
- Chinese Academy of Sciences
- Brief Summary
Due to the occult anatomic location of the nasopharynx and frequent presence of adenoid hyperplasia, the positive rate for nasopharyngeal carcinoma identification during biopsy is low, thus leading to delayed or missed diagnosis for nasopharyngeal carcinoma upon initial attempt. Here, we aimed to develop an artificial intelligence tool to detect nasopharyngeal malignancies and guide biopsy under endoscopic examination based on deep learning.
- Detailed Description
Due to the occult anatomic location of the nasopharynx and frequent presence of adenoid hyperplasia, the positive rate for nasopharyngeal carcinoma identification during biopsy is low, thus leading to delayed or missed diagnosis for nasopharyngeal carcinoma upon initial attempt. Here, we aimed to develop an artificial intelligence tool to detect nasopharyngeal malignancies and guide biopsy under endoscopic examination based on deep learning.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
- The patient was found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy and the clinicans considered it necessary to perform an biopsy.
- Hemilateral lesion with limited size.
- Patients with nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, etc. who have already been treated.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Aera under the receiver operating characteristic curve (AUC) three months AUC of an deep learning-based model in discriminating nasopharyngeal carcinoma from bengin lesion.
- Secondary Outcome Measures
Name Time Method Accuray three months The agreement between the deep learning-based model and the histopathological diagnosis of the three biopsy specimens (inside the lesion, 5-8 mm outside the lesion, and 8-10 mm outside the lesion).
Trial Locations
- Locations (5)
Fujian Provincial Cancer Hospital
🇨🇳Fuzhou, Fujian, China
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University
🇨🇳Guangzhou, Guangdong, China
Sun Yat-Sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China
Hainan Provincial People's Hospital
🇨🇳Haikou, Hainan, China
Fujian Provincial Cancer Hospital🇨🇳Fuzhou, Fujian, ChinaSufang QiuContact